Serum neurofilament light chain – A potential biomarker for polyneuropathy in type 2 diabetes?
Authors' conclusion
S-NfL is unlikely to be a reliable biomarker for the presence of DPN. S-NfL is however associated tothe severity of the nerve damage underlying DPN.
Study context
- Population
- People with screen-detected T2D from the ADDITION-Denmark cohort, plus healthy controls178 T2D + 32 controls
- Exposure
- T2D with diabetic polyneuropathy (DPN) vs without DPN vs healthy controls
- DPNn = 39
- Controlsn = 32
- Outcome
- Relationship between serum NfL and presence and severity of DPN
Main finding
As reported in the abstract
Serum NfL
- AUC of Serum NfL (s-NfL) for DPN
- 0.63 (95% CI 0.52; 0.73)
Observational data: associations, not effects.
Further findings
Association of nerve conduction study (NCS) sum z-scores (per 1 SD) with s-NfL
- Higher original NCS sum z-score: % higher s-NfL
- 10.2 (95% CI 4.0; 16.8)
- Higher axonal NCS sum z-score: % higher s-NfL
- 12.1 (95% CI 6.6; 17.9)
Original publication
Serum neurofilament light chain – A potential biomarker for polyneuropathy in type 2 diabetes? Diabetes Res Clin Pract. Published 30 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →